Show simple item record

dc.contributor.authorNeoptolemos, JPen_US
dc.contributor.authorPalmer, DHen_US
dc.contributor.authorGhaneh, Pen_US
dc.contributor.authorPsarelli, EEen_US
dc.contributor.authorValle, JWen_US
dc.contributor.authorHalloran, CMen_US
dc.contributor.authorFaluyi, Oen_US
dc.contributor.authorO'Reilly, DAen_US
dc.contributor.authorCunningham, Den_US
dc.contributor.authorWadsley, Jen_US
dc.contributor.authorDarby, Sen_US
dc.contributor.authorMeyer, Ten_US
dc.contributor.authorGillmore, Ren_US
dc.contributor.authorAnthoney, Aen_US
dc.contributor.authorLind, Pen_US
dc.contributor.authorGlimelius, Ben_US
dc.contributor.authorFalk, Sen_US
dc.contributor.authorIzbicki, JRen_US
dc.contributor.authorMiddleton, GWen_US
dc.contributor.authorCummins, Sen_US
dc.contributor.authorRoss, PJen_US
dc.contributor.authorWasan, Hen_US
dc.contributor.authorMcDonald, Aen_US
dc.contributor.authorCrosby, Ten_US
dc.contributor.authorMa, YTen_US
dc.contributor.authorPatel, Ken_US
dc.contributor.authorSherriff, Den_US
dc.contributor.authorSoomal, Ren_US
dc.contributor.authorBorg, Den_US
dc.contributor.authorSothi, Sen_US
dc.contributor.authorHammel, Pen_US
dc.contributor.authorHackert, Ten_US
dc.contributor.authorJackson, Ren_US
dc.contributor.authorBüchler, MWen_US
dc.contributor.authorEuropean Study Group for Pancreatic Canceren_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2017-03-27T12:32:04Z
dc.date.issued2017-03-11en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28129987en_US
dc.identifierS0140-6736(16)32409-6en_US
dc.identifier.citationLancet, 2017, 389 (10073), pp. 1011 - 1024en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/534
dc.identifier.eissn1474-547Xen_US
dc.identifier.doi10.1016/S0140-6736(16)32409-6en_US
dc.description.abstractBACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer. METHODS: We did a phase 3, two-group, open-label, multicentre, randomised clinical trial at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden. Eligible patients were aged 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection). We randomly assigned patients (1:1) within 12 weeks of surgery to receive six cycles of either 1000 mg/m2 gemcitabine alone administered once a week for three of every 4 weeks (one cycle) or with 1660 mg/m2 oral capecitabine administered for 21 days followed by 7 days' rest (one cycle). Randomisation was based on a minimisation routine, and country was used as a stratification factor. The primary endpoint was overall survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat population. Toxicity was analysed in all patients who received trial treatment. This trial was registered with the EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434. FINDINGS: Of 732 patients enrolled, 730 were included in the final analysis. Of these, 366 were randomly assigned to receive gemcitabine and 364 to gemcitabine plus capecitabine. The Independent Data and Safety Monitoring Committee requested reporting of the results after there were 458 (95%) of a target of 480 deaths. The median overall survival for patients in the gemcitabine plus capecitabine group was 28·0 months (95% CI 23·5-31·5) compared with 25·5 months (22·7-27·9) in the gemcitabine group (hazard ratio 0·82 [95% CI 0·68-0·98], p=0·032). 608 grade 3-4 adverse events were reported by 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse events in 196 of 366 patients in the gemcitabine group. INTERPRETATION: The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma. FUNDING: Cancer Research UK.en_US
dc.format.extent1011 - 1024en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAntimetabolites, Antineoplasticen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectCapecitabineen_US
dc.subjectCarcinoma, Pancreatic Ductalen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectDeoxycytidineen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectKaplan-Meier Estimateen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPancreatic Neoplasmsen_US
dc.subjectTreatment Outcomeen_US
dc.titleComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-28en_US
rioxxterms.versionofrecord10.1016/S0140-6736(16)32409-6en_US
rioxxterms.licenseref.startdate2017-03-11en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfLanceten_US
pubs.issue10073en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume389en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/